Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Cyclosporin A sensitises Bcr-Abl positive cells to imatinib mesylate independently of P-glycoprotein expression

I Frydrych, P Mlejnek, P Dolezel

. 2009 ; 23 (8) : 1482-1490.

Language English Country Great Britain

Document type Research Support, Non-U.S. Gov't

Grant support
NR9482 MZ0 CEP Register

The effect of cyclosporin A (CsA) on imatinib treated Bcr-Abl positive K562 cells was studied. Similarly to other authors we found that imatinib induced apoptosis and erythroid differentiation in K562 cells. While its low concentrations induced predominantly erythroid differentiation, higher concentrations induced apoptosis. We found that CsA significantly potentiated cytotoxic effects of imatinib. A detailed analysis revealed that CsA shifted the balance between differentiation and apoptosis in favour of apoptosis. Our findings indicated that the observed effect of CsA was mediated neither through inhibition of ERK1/2 (extracellular signal-regulated kinases 1/2), nor through inhibition of p38 MAPK. We further observed that CsA might sensitise cells to apoptosis due to a changed cellular redox status as combined treatment of cells with imatinib and CsA resulted in a dramatic decrease of the ratio between reduced (GSH) and oxidised (GSSG) glutathione GSH/GSSG and in a significant suppression of thioredoxin reductase enzymatic activity. Our results indicated that K562 cells did not express detectable level of P-glycoprotein (P-gp). In addition, CsA did not affect significantly the intracellular level of imatinib. Therefore we excluded the possibility that CsA increased sensitivity of cells to imatinib by the inhibition of P-gp-mediated drug efflux or by another mechanism involving modulation of intracellular drug concentration.

000      
03115naa a2200409 a 4500
001      
bmc12009167
003      
CZ-PrNML
005      
20140717082728.0
008      
120319s2009 xxk eng||
009      
AR
040    __
$d ABA008 $a ABA008 $b cze
041    0_
$a eng
044    __
$a xxk
100    1_
$a Frydrych, Ivo $7 xx0169396 $u Department of Biology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc
245    10
$a Cyclosporin A sensitises Bcr-Abl positive cells to imatinib mesylate independently of P-glycoprotein expression / $c I Frydrych, P Mlejnek, P Dolezel
520    9_
$a The effect of cyclosporin A (CsA) on imatinib treated Bcr-Abl positive K562 cells was studied. Similarly to other authors we found that imatinib induced apoptosis and erythroid differentiation in K562 cells. While its low concentrations induced predominantly erythroid differentiation, higher concentrations induced apoptosis. We found that CsA significantly potentiated cytotoxic effects of imatinib. A detailed analysis revealed that CsA shifted the balance between differentiation and apoptosis in favour of apoptosis. Our findings indicated that the observed effect of CsA was mediated neither through inhibition of ERK1/2 (extracellular signal-regulated kinases 1/2), nor through inhibition of p38 MAPK. We further observed that CsA might sensitise cells to apoptosis due to a changed cellular redox status as combined treatment of cells with imatinib and CsA resulted in a dramatic decrease of the ratio between reduced (GSH) and oxidised (GSSG) glutathione GSH/GSSG and in a significant suppression of thioredoxin reductase enzymatic activity. Our results indicated that K562 cells did not express detectable level of P-glycoprotein (P-gp). In addition, CsA did not affect significantly the intracellular level of imatinib. Therefore we excluded the possibility that CsA increased sensitivity of cells to imatinib by the inhibition of P-gp-mediated drug efflux or by another mechanism involving modulation of intracellular drug concentration.
590    __
$a bohemika - dle Pubmed
650    02
$a protinádorové látky $x farmakologie $7 D000970
650    02
$a apoptóza $x účinky léků $7 D017209
650    02
$a cyklosporin $x farmakologie $7 D016572
650    02
$a extracelulárním signálem regulované MAP kinasy $x antagonisté a inhibitory $7 D048049
650    02
$a bcr-abl fúzní proteiny $x analýza $7 D016044
650    02
$a glutathion $x analýza $7 D005978
650    02
$a glutathiondisulfid $x analýza $7 D019803
650    02
$a lidé $7 D006801
650    02
$a imidazoly $x farmakologie $7 D007093
650    02
$a buňky K562 $7 D020014
650    02
$a P-glykoprotein $x analýza $x fyziologie $7 D020168
650    02
$a piperaziny $x farmakologie $7 D010879
650    02
$a pyridiny $x farmakologie $7 D011725
650    02
$a pyrimidiny $x farmakologie $7 D011743
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Mlejnek, Petr, $d 1963- $7 xx0023808
700    1#
$a Doležel, Petr. $7 xx0317513
773    0_
$t Toxicology in Vitro $p Toxicol In Vitro $g Roč. 23, č. 8 (2009), s. 1482-1490 $x def $w MED00004536
773    0_
$p Toxicol In Vitro $g 23(8):1482-90, 2009 Dec
910    __
$a ABA008 $b x $y 4 $z 0
990    __
$a 20120319150915 $b ABA008
991    __
$a 20140717083030 $b ABA008
999    __
$a ok $b bmc $g 902390 $s 766073
BAS    __
$a 3
BMC    __
$a 2009 $b 23 $c 8 $d 1482-1490 $i def $m Toxicology in vitro $x MED00004536
GRA    __
$a NR9482 $p MZ0
LZP    __
$a 2012-1Q10/

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...